CXLens^®

Quantitative Cross-linking Lens

UV Delivery + Biomechanical Monitoring

CXLens^® is applied to the scleral surface of the eye (vaulting over the cornea) following administration of Vitamin B2 (Riboflavin) eye drops. CXLens emits patterned Ultraviolet (UV) light to crosslink specific areas of the cornea CXLens UV illumination continues until an on-board sensor and algorithms determine that certain biomechanical properties of the corneal stroma have been adjusted to pre-planned values.. This closed loop dosing allows for , precise control over corneal shape and this should be able to predictably improve a patient’s vision.

Integrated Real-time Ultrasound Elastography
Patterned Ultraviolet Light Delivery
Proprietary Riboflavin Driver Technology for Intact Epithelium Procedures
Planned for a single treatment less than 30 min
Simultaneous bilateral treatment possible.

Comfortable, Precise, Personalized Treatment

The scleral design of CXLens is very comfortable for the patient and stable on the eye. Patients can be treated with eyes opened or closed, sitting upright in a chair or lying down. The contact lens form factor is familiar to contact lens wearers, helping to eliminate the fear associated with laser correction procedures.

The scleral lens platform moves with the eye during treatment, reducing or eliminating patient motion artifacts and the need for complex eye motion tracking hardware and algorithms.
As CXLens moves with the eye the UV can be targeted only to selected zones of the cornea.
This degree of stability is required for refractive indications and should provide for more efficacious Keratoconus cross-linking treatment as the patient cannot look away from the light.
No eyelid speculum required.

qCXL^(TM) for Accurate Refractions

CXLens is unique in the corneal cross-linking field enabling Quantitative Cross-linking (qCXL). Sitting directly on the eye, it’s built-in Ultrasound transducer provides real-time elastography feedback during cross-linking helping to enabling precise, customized closed loop dosing (selective stiffening of the corneal surface) required for predictable refractive outcomes.

CXLens cross-section

CXLens Ultrasound Transducer

Ultrasound is transmitted through the UV beam (not possible with off-eye crosslinking systems) to measure real-time biomechanical parameters.

TECLens / SERVImed Proprietary Trans-Epithelial Riboflavin

Simplicity and Scale

TECLens provides a technologically advanced cross-linking platform without sacrificing operational simplicity and affordability.

The small inexpensive control system will offer easy market entry access to cross-linking and refractive correction
The TECLens system was designed with the busy practice in mind making it economic to treat multiple eyes and patients simultaneously
Patients can be treated in an exam room sitting up, with no need for a surgical suite or multiple attending staff, which, for Keratoconus patients could mean upto a 400% increase in efficiency for the practitioner. Treating two eyes at once is simply not possible with any other cross-linking system.

Benefits

For Patients

Non-invasive, transepithelial approach
No 'LASIK fear factor
Comfortable; eyes closed or open
Therapy in an exam room
Positional stability
Personalized pre-planning to help ensure accurate prescriptions and outcomes
Both eyes can be treated simultaneously

For Physicians

Low cost of entry into the refractive market
Control over procedure margin
Designed for high patient throughput
Multiple patients can be treated simultaneously
Small clinical footprint
No assistant required

Target Indications

Keratoconus

Corneal Ectasia following refractive surgery

Pediatric Progressive Myopia

Low Myopia

Presbyopia

Hyperopia

Refractive Tune-up after IOL placement

US Patents 9,883,970 | 9,861,526 | 9,907,698 | 10,010,449 | 10,548,772 | 10,548,773 (and corresponding OUS Patents), and several Patents Pending. TECLens^® & CXLens^® are Registered Trademarks of TECLens, Inc.

CXLens®